GSK Strengthens mRNA Capabilities with Strategic $1.56B Acquisition of CureVac’s Vaccine Portfolio

London, July 3, 2024 (Reuters) -- In a strategic move to enhance its mRNA technology portfolio, British pharmaceutical giant GSK has acquired full rights to CureVac's experimental vaccines targeting COVID-19 and influenza. This acquisition, begins with a $435 Million upfront payment and provides a critical financial lifeline to CureVac.

Read full article here.